Compare TATT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TATT | PRTC |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.9M | 400.2M |
| IPO Year | 2002 | N/A |
| Metric | TATT | PRTC |
|---|---|---|
| Price | $36.12 | $17.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $57.17 | N/A |
| AVG Volume (30 Days) | ★ 175.9K | 12.2K |
| Earning Date | 05-18-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.29 | N/A |
| Revenue Next Year | $16.09 | N/A |
| P/E Ratio | $38.61 | ★ $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.52 | $14.50 |
| 52 Week High | $64.50 | $19.92 |
| Indicator | TATT | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 51.72 |
| Support Level | $33.70 | $16.69 |
| Resistance Level | $41.27 | $18.70 |
| Average True Range (ATR) | 1.53 | 0.76 |
| MACD | 0.37 | -0.08 |
| Stochastic Oscillator | 44.35 | 27.45 |
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.